Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia
Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia
复制标题
DOI:
10.1097/00001756-199812010-00006
复制
发表时间:
1998-12-01
期刊:
影响因子:
1.7
通讯作者:
Anisman, H
中科院分区:
文献类型:
--
作者:
Borowski, T;Kokkinidis, E;Anisman, H
SYSTEMIC administration of lipopolysaccharide (LPS), a non-specific activator of proinflammatory cytokine release from macrophages, provokes sickness characterized by anorexia, soporific effects, and disturbances of locomotor activity and exploration. In addition, endotoxin treatment may provoke an anhedonic response. Assessment of anhedonia in appetitive paradigms, however, is compromised by the anorexia provoked resent investigation assessed by the treatment. The LPS on rewarding lateral the anhedonic effects hypothalamic brain stimulation. Using a simultaneous discrimination, current titration procedure in the assessment of intracranial self-stimulation (ICSS), it was found that acute systemic administration of LPS (50 mu g, 100 mu g or 200 mu g) reduced ICSS during the ascending sequence of current presentations, but had little effect on responding to a series of descending currents. In a parallel experiment, peripheral administration of LPS (100 mu g) increased in vivo dopamine (DA) efflux from the nucleus accumbens, a region thought to be involved in goal-directed responding to positively reinforcing stimuli. It is suggested that LPS alters ICSS in a manner different than that observed following stressor exposure or peripheral IL-2 treatment. Furthermore, LPS may engender an anhedonic effect (possibly secondary to sickness), and the decline of responding reflects the relation between the cost of responding given in the face of sickness and the reward received for responding. NeuroReport 9: 3797-3802 (C) 1998 Lippincott Williams & Wilkins.